Key Highlights

  • PMV Pharmaceuticals (NASDAQ:PMVP) was quoted at USD 1.39 pre-market on Tuesday, November 10, 2026, up 11.27% from a calculated prior close of USD 1.25 set in the November 9 session.
  • Published market data from October 26, 2026 showed a Market Value of USD 85.33 million, 75.51 million shares outstanding and a 52-week range of USD 1.02 to USD 1.91.
  • Cash was USD 112.9 million on December 31, 2025, against USD 183.3 million a year earlier, a fall of USD 70.4 million (calculated), which keeps funding in focus.
  • No catalyst was identified in published coverage; third-quarter results are estimated for November 11, 2026, and six analysts carry an average target of USD 4.20.

What Moved PMV Pharmaceuticals Pre-Market (+11.27%)

The pre-market screener snapshot taken before the open on November 10, 2026 shows PMV Pharmaceuticals at USD 1.39, a gain of 11.27%. Simple arithmetic on those two published numbers gives a prior close of about USD 1.25, so the move equals roughly USD 0.14 per share. At 75.51 million shares, the pre-market quote implies a market value near USD 104.96 million (calculated), against USD 85.33 million when the stock closed at USD 1.13 on October 26, 2026 after a fall of 11.02%. That session traded 648,579 shares. The pre-market quote is therefore about 23.0% above the October 26 close (calculated). The share count on that page may predate the August 31, 2026 offering, so the implied value is indicative only.

The Rationale: Catalyst or No Catalyst

No company release or filing dated November 9 or November 10, 2026 was found in published coverage, so no catalyst is identified. The most recent company items were the August 31, 2026 pricing of an oversubscribed USD 50 million public offering, a 42 million share secondary priced at USD 1.21, updated ovarian cancer data from the PYNNACLE trial and the appointment of Philip Herman as chief commercial officer. The second-quarter report on August 14, 2026 showed a per-share result of USD 0.34 against a consensus of USD 0.40. As general context, pre-market gains in clinical-stage biotechs often reflect positioning ahead of an Earnings date, short covering, sector rotation or a single buyer in a thin book. Which of these applies here is not known.

Valuation, Liquidity and Risks

At USD 1.39, the stock sits 27.2% below the 52-week high of USD 1.91 and about 36.3% above the 52-week low of USD 1.02 (calculated). The average analyst target of USD 4.20 from six analysts is roughly 202% above the pre-market quote, a gap that reflects binary clinical risk more than near-term pricing. Pre-market Volume is typically a small fraction of regular volume, so a few trades can move the price, and bid-ask spreads can be wide. The cash decline of USD 70.4 million in a year, the dilution from the August 2026 financing and the possibility that the gain reverses at the 9:30 a.m. ET open are the main risks. Nothing here suggests the move will continue.

Where Things Stand

PMV Pharmaceuticals (NASDAQ:PMVP) is up 11.27% pre-market at USD 1.39 without an identified catalyst. The USD 85.33 million market value, USD 112.9 million of cash at the end of 2025 and an estimated November 11, 2026 earnings date frame the setup. Thin trading means the quote may not hold into the regular session.